BiotechTube
Home/Pipeline/CAR‑iNK‑OvCa

CAR‑iNK‑OvCa

Ovarian Cancer

PreclinicalActive

Key Facts

Indication
Ovarian Cancer
Phase
Preclinical
Status
Active
Company
Cartherics

About Cartherics

Australian biotech delivering off‑the‑shelf CAR‑NK and EV immunotherapies for women’s cancers and endometriosis.

View full company profile

Therapeutic Areas

OncologyGynecologyImmunology

Other Ovarian Cancer Drugs

DrugCompanyPhase
EXO‑Ovarian Cancer TestINOVIQPhase 2/3
MagSense™ FR Imaging AgentImagion BiosystemsPre‑clinical
Yondelis (trabectedin)PharmaMarApproved
Measovir®-based candidateOncovitaPre-clinical
NP-G2-044 + Chemotherapy AgentsNovita PharmaceuticalsPhase 2a
Ivospemin (SBP-101)Panbela TherapeuticsPhase 2
Ovarian Cancer Early Detection AssayGenEndeavorPre-clinical
INVAC-1InvectysPhase 2
Folate Receptor-Targeted PCCIndi MolecularPreclinical
Immunomodulator PlatformOmniCytePre-clinical
Platform CandidateFLAG TherapeuticsPreclinical
High Internalization ADCLytica TherapeuticsPreclinical